. Eli Lilly & Co halted development of an experimental cancer drug after the medicine failed to lengthen survival for certain lymphoma patients in a study. The decision will result in a charge of $30 million in the second quarter, Indianapolis based Lilly said in a statement today. The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018, according to Mark Schoenebaum, an analyst with ISI Group. Lilly said in April it was expecting to seek U. S regulatory approval this year for the drug to prevent the relapse of diffuse large b cell lymphoma, a type of blood cancer 
Share:  . <span class="company">Eli</span> Lilly & Co halted development of an experimental cancer drug after the medicine failed to lengthen survival for certain lymphoma patients in a study. The decision will result in a charge of $30 million in the second quarter, Indianapolis based Lilly said in a statement today.<span class="sent"> The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018, according to <span class="analyst">Mark Schoenebaum</span>, an analyst with ISI Group.</span> Lilly said in April it was expecting to seek U. S regulatory approval this year for the drug to prevent the relapse of diffuse large b cell lymphoma, a type of blood cancer..... <span class="company">Eli</span> Lilly & Co halted development of an experimental cancer drug after the medicine failed to lengthen survival for certain lymphoma patients in a study. The decision will result in a charge of $30 million in the second quarter, Indianapolis based Lilly said in a statement today.<span class="sent"> The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018, according to <span class="analyst">Mark Schoenebaum</span>, an analyst with ISI Group.</span> Lilly said in April it was expecting to seek U. S regulatory approval this year for the drug to prevent the relapse of diffuse large b cell lymphoma, a type of blood cancer....Eli <span class="company">Lilly</span> & Co halted development of an experimental cancer drug after the medicine failed to lengthen survival for certain lymphoma patients in a study. The decision will result in a charge of $30 million in the second quarter, Indianapolis based <span class="company">Lilly</span> said in a statement today.<span class="sent"> The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018, according to <span class="analyst">Mark Schoenebaum</span>, an analyst with ISI Group.</span> <span class="company">Lilly</span> said in April it was expecting to seek U. S regulatory approval this year for the drug to prevent the relapse of diffuse large b cell lymphoma, a type of blood cancer. ....<span class="sent">The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018, according to <span class="analyst">Mark Schoenebaum</span>, an analyst with ISI Group.</span> <span class="company">Lilly</span> said in April it was expecting to seek U. S regulatory approval this year for the drug to prevent the relapse of diffuse large b cell lymphoma, a type of blood cancer. . . . Tweet this   read full story